US 11,718,618 B2
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
Nicole Harriott, San Diego, CA (US); Nicholas Pagano, San Diego, CA (US); and Byron A. Boon, San Diego, CA (US)
Assigned to Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed by Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed on Jan. 12, 2023, as Appl. No. 18/96,073.
Application 18/096,073 is a continuation of application No. PCT/US2022/021080, filed on Mar. 21, 2022.
Claims priority of provisional application 63/164,135, filed on Mar. 22, 2021.
Prior Publication US 2023/0159528 A1, May 25, 2023
Int. Cl. A61K 31/4353 (2006.01); C07D 471/14 (2006.01); C07D 471/04 (2006.01); A61P 25/18 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 25/18 (2018.01)] 28 Claims
 
1. A compound of Formula (Ia):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is:

OG Complex Work Unit Chemistry
 
6. A pharmaceutical product comprising at least one pharmaceutically acceptable excipient and a compound according to claim 1, or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical product is selected from the group consisting of a kit, a pharmaceutical composition, a pharmaceutical formulation, and a pharmaceutical unit dosage form.